Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/10/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
09/29/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
09/27/2023 8-K Quarterly results
08/22/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/11/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 D Form D - Notice of Exempt Offering of Securities:
07/21/2023 8-K Quarterly results
07/20/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/20/2023 8-K Quarterly results
05/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 8-K Quarterly results
04/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’ s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’ s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal Models"
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/24/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
12/23/2022 8-K Quarterly results
12/16/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
12/06/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
10/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP"
10/11/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/26/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/15/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
08/10/2022 10-Q Quarterly Report for the period ended June 30, 2022
06/24/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy